Table 2.

Results of the meta-analyses of intensive glycaemic control

Boussageon6Hemmingsen7
Trials, N1320
Patients, N34 53329 486
Δ HbA1c (%)0.80–
Confidence interval99%95%
Overall mortalityRR (99% CI)RR (95% CI)
1.04 (0.91 to 1.19)1.01 (0.90 to 1.13)
CV mortality1.11 (0.86 to 1.43)1.06 (0.90 to 1.26)
Non-fatal MIa0.85 (0.74 to 0.96)0.87 (0.76 to 1.00)
Stroke0.96 (0.83 to 1.13)0.96 (0.80 to 1.16)
Congestive heart failure1.17 (0.91 to 1.50)NR
Nephropathy0.90 (0.85 to 0.96)b0.83 (0.64 to 1.06)
Retinopathy0.85 (0.71 to 1.03)0.80 (0.67 to 0.94)c
Neuropathy0.99 (0.95 to 1.03)NR
Severe hypoglycaemia2.33 (1.62 to 3.36)2.05 (1.39 to 2.02)

  • ↵a Secondary endpoint.

  • ↵b Albuminuria.

  • ↵c Composite endpoint. CV = cardiovascular mortality. MI = myocardial infarction. NR = not reported. RR = relative risk. Bold = significant.